If the LPI-GPR55 system can be consistently linked to liver injury, it will be exciting to test whether GPR55 antagonists can provide therapeutic benefit in ALD, NAFLD, or viral hepatitis. This evidence concerns the gene GPR55 and animal viral hepatitis.